###### Strengths and limitations of this study

-   An initial description of the concentration versus time relationship for menthol following administration of a proprietary peppermint oil (PMO) formulation to treat paediatric patients with irritable bowel syndrome (IBS).

-   A basis for the design of future paediatric investigations of PMO to characterise the exposure--response relationship for menthol in children with IBS.

-   A small study cohort which, while providing descriptive information regarding the clinical pharmacology of menthol from PMO in paediatric patients with IBS, may not reflect the true population variability in the dose versus exposure relationship.

Introduction {#s1}
============

Peppermint oil (PMO) (Menthae piperitae aetheroleum) is obtained by steam distillation from the fresh leaves of peppermint (*Mentha piperita* L). The major constituents of PMO include the terpenes (−) menthol (30--50%), (−) menthone (14--32%), (+) isomenthone (1.5--10%), (−) menthyl acetate (2.8--10%), (+) menthofuran (1.0--9.0%), and 1,8-cineol (3.5--14%). As reviewed by Grigoleit and Grigoleit,[@R1] the pharmacologically active ingredient of PMO is menthol that in nature exists as a pure stereoisomer (1*R*,2*S*,5*R*)-2-Isopropyl-5-methylcyclohexanol).

Through its ability to act as a calcium antagonist, menthol appears to have a spasmolytic effect in the gastrointestinal tract. Consequently, PMO has been used to treat abdominal ailments in ancient Egypt, Greece and Rome,[@R2] and anecdotal evidence of its purported efficacy abounds to this day. A review and several meta-analyses of randomised, double blind, placebo-controlled trials in adults have demonstrated that PMO is effective in reducing abdominal pain in patients with irritable bowel syndrome (IBS).[@R1] [@R3] However, in children with IBS, there is a dearth of information restricted to a single small (n=42), double blind, placebo-controlled trial.[@R7] Nonetheless, the use of PMO as an adjunctive measure to treat children with IBS continues to evolve in clinical practice despite the lack of any information pertaining to the impact of age and/or disease state on its pharmacodynamics (PDs) or pharmacokinetics (PKs). Thus, dosing remains empiric in paediatric patients and adults, where a range in daily doses of more than 2.5-fold has been reported.[@R1]

Given the increasing use of PMO in paediatric patients with IBS and the potential for developmental changes to influence the PKs and PDs of drugs,[@R8] we conducted an exploratory, pilot PK study of menthol following the administration of a proprietary formulation of PMO in a cohort of paediatric patients with IBS. The primary objective of this study was to examine the concentration versus time profile of menthol following a single PMO dose and to describe its apparent PK.

Methods {#s2}
=======

Patients {#s2a}
--------

We performed a single-site, proof-of-principle exploratory study of menthol PKs following a single 187 mg oral dose of PMO (Colpermin capsule; Tillotts Pharma, Rheinfelden, Switzerland). Patients with paediatric Rome III defined IBS (n=6), who had no intercurrent illness or recent change in IBS symptoms, were enrolled into a protocol approved by the Baylor College of Medicine Institutional Review Board. Children initially were identified by review of medical records. They were screened by telephone to be sure they qualified and that IBS symptoms were current. They were otherwise healthy. Absence of illness was assessed via history and physical examination at the time of the study visit. No participant was receiving therapeutic medications and/or natural products known to influence the activity of either hepatic drug metabolism (ie, no enzyme inducers or inhibitors) or renal drug clearance. Finally, other than an existing diagnosis of IBS, no study participant had a history of an abnormality or surgery of the gastrointestinal tract.

All study participants were enrolled by informed parental consent and when appropriate (eg, \>6 years of age), by patient assent. Informed consent was documented prior to performing any study-related procedure.

Drug administration, sampling and sample handling {#s2b}
-------------------------------------------------

The clinical phase of this study was conducted in strict accordance with good clinical practice principles. Prior to being admitted to the Metabolic Research Unit (MRU) at the Children\'s Nutrition Research Center, study participants were fasted from midnight immediately preceding the morning of admission (ie, overnight). Following the history, physical examination and recording of vital signs (temperature, pulse rate, respiratory rate, seated blood pressure), a venous cannula (21 gauge) was aseptically placed in a large vein either in the dorsum of the hand or on the volar surface of the lower arm to facilitate obtaining repeated blood samples to support the PK objectives of the study. The cannula was secured and its patency maintained through periodic flushing of the dead space with sterile 0.9% sodium chloride.

At approximately 09:00, subjects received a single oral dose of PMO given as a commercially available, proprietary, non-prescription product (Colpermin, each capsule containing approximately 83.0 mg of menthol as a constituent of PMO) followed by 120 mL of water at 25°C. Immediately prior to administration of the test article, a blood sample (2.0 mL) was obtained. After PMO administration, repeated blood samples (2.0 mL each) were obtained directly into green top glass tubes containing sodium heparin (Vacutainer, Becton Dickinson, East Rutherford, New Jersey, USA) at the following postdose time points: 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 h. At 2 h after PMO administration, participants were given a standardised meal. Throughout the 12 h study period, participants were restricted from any strenuous physical exercise. After completion of the final (12 h) sample, vital signs were reassessed, the venous cannula was removed and the insertion site evaluated for redness, swelling and/or bruising. Study participants were then discharged from the MRU and received a follow-up call from a clinical research coordinator, approximately 24 h thereafter, to specifically assess/evaluate any potential adverse effects.

Immediately following collection of a given blood sample, it was mixed by gentle inversion and the tube immediately placed at 4°C. At 4 h intervals, blood samples were centrifuged (2500*g* for 10 min at 4°C). The resultant plasma from each tube then was immediately transferred into a clean, screw-capped polypropylene tube and immediately frozen at −80°C. Samples were maintained at 2--8°C while handling so as to minimise evaporative loss of any volatile compounds contained therein.

Analytical {#s2c}
----------

Total (ie, conjugated and unconjugated) menthol in plasma was measured by gas chromatography mass spectrometry (GC-MS), as described in previous methods, with several minor modifications.[@R9] [@R10] Briefly, to 0.5 mL of the patient\'s heparinised plasma or controls or calibrators, 20 µL internal standard (menthol-d4, 10 µg/mL), 25 µL β-glucuronidase (90 000 U/mL), and 10 µL sodium acetate buffer (pH 4.8) were added. The mixture was incubated overnight in air-tight tubes in 37°C water bath and into each tube, 150 µL 0.4 M phosphate buffer (pH 4.8) was added. Menthol was extracted in 0.5 mL methylene chloride by rocking the tubes for 5 min. The mixture was centrifuged at 2000*g* for 5 min. The methylene chloride layer was transferred to an auto-sampler vial and a 2 µL extract was injected onto the GC-MS (Agilent Technologies, Santa Clara, California, USA) installed with ZB-1MS 15×250×0.25 µm column. Ions (m/z) monitored for quantification and identification were 138, 123, 95 for menthol and 142, 127, 99 for menthol-d4. The data were analysed using Target Software (Thru-Put Systems, Orlando, Florida, USA). The quantitative ions were used to construct standard curves of the peak area ratios (calibrator/internal standard pair). The assay was linear within the range of concentrations evaluated 5--1000 ng/mL (r^2^\>0.99). For all standards, the intra-assay and inter-assay coefficient of variations (CVs) were \<10%.

PK data analysis {#s2d}
----------------

Menthol plasma concentration versus time data were evaluated using a model independent approach. Individual Cmax and Tmax were obtained by direct examination of the plasma concentration versus time profile. The area under the plasma concentration versus time curve during the sampling period (AUC~0-n~) was calculated using the mixed log-linear method where 'n' refers to the final sampling time with quantifiable menthol concentrations. The terminal elimination rate constant (λz) was estimated using an iterative least-squares regression algorithm when a sufficient number of postpeak concentrations were available to support a reliable estimation of the parameter. When possible, the total AUC (AUC~tot~) was extrapolated to infinity by dividing λz into the predicted plasma concentration at the end of the sampling interval. As a subset of our patients (n=3) did not have \>3 post-Cmax plasma concentrations, there was significant uncertainty associated with the estimation of λz and consequently, the PK parameters that rely on the terminal rate constant (eg, AUC to infinity (AUC~0-∞~), apparent oral clearance (Cl/F), and apparent volume of distribution at steady-state (Vss/F)) are not reported. Menthol PK data were examined using standard descriptive statistics. A priori determination of statistical power was not considered given that this was the first PK study performed in a paediatric cohort; the goal of this exploratory study was descriptive and no comparisons (ie, within group or between group) of PK data were undertaken. All analyses were performed in Kinetica V.5.1 (Thermo Scientific) and SPSS V.20 (IBM SPSS).

Results {#s3}
=======

All six participants completed the study without experiencing any apparent adverse events. The study cohort consisted of four female and two male patients. Their age range was 7--12 years (10.3±1.9 years.), and their body weights ranged from 26.6 to 58.2 kg (45.2±11.5 kg). None of the participants had a height or weight which was outside of the 5--95th centile for age.

The composite (mean±95% confidence limits) and individual plasma menthol concentration versus time data are shown in panels A and B of the [figure 1](#BMJOPEN2015008375F1){ref-type="fig"}, respectively. Considerable intersubject variability in the plasma concentration versus time profiles was apparent with all participants in the cohort. Individual PK parameters for menthol are provided in [table 1](#BMJOPEN2015008375TB1){ref-type="table"}. The time of appearance (Tmax) for apparent peak plasma concentrations (Cmax) ranged from 2.5 to 8 h following a lag time (Tlag) which ranged from 1.5 to 4 h. Absolute Cmax values ranged from 458 to 1056 ng/mL, which when corrected to a weight-adjusted menthol dose received by each child ranged from 255 to 470 ng/mL per 1 mg/kg (ie, an approximate 1.8-fold difference). The dose normalised systemic menthol exposure reflected by the area under the plasma concentration versus time curve (AUC per mg/kg dose) varied over an approximate twofold range (1464.1 to 2941.1 ng/mL×h). Given the marked delay in the appearance of menthol in plasma after a PMO dose, sufficient postpeak plasma concentrations to reliably estimate an apparent elimination rate constant (λz) and elimination half-life were not available in all participants. Consequently, the non-compartmental parameter mean residence time (MRT; a time representing elimination of approximately 60% of a given dose from the body) was determined using statistical moment theory and ranged from 6.4 to 9.4 h ([table 1](#BMJOPEN2015008375TB1){ref-type="table"}).

###### 

Individual menthol pharmacokinetic parameters

  Participant   Menthol dose (mg/kg)   Cmax (ng/mL)   Cmax (ng/mL per mg/kg dose)   Tmax (h)   Tlag (h)   AUClast (ng/mL×h per mg/kg dose)   AUCtot (ng/mL×h per mg/kg dose)   MRT (h)
  ------------- ---------------------- -------------- ----------------------------- ---------- ---------- ---------------------------------- --------------------------------- ---------
  MentPK-01     1.4                    628            445.1                         2.5        1.5        2941.1                             3199.2                            7.0
  MentPK-02     1.5                    474            325.0                         6          1          2045.6                             2245.9                            7.5
  MentPK 03     2.0                    936            470.5                         4          2          1951.4                             2137.1                            6.4
  MentPK 04     3.1                    1056           342.1                         8          4          1198.4                             1350.5                            9.1
  MentPK 05     1.9                    637            332.8                         3          1.5        2107.2                             2434.8                            7.4
  MentPK 06     1.8                    458            255.5                         8          2          1464.1                             1879.5                            9.4

AUC, area under the plasma concentration versus time curve; Cmax, apparent peak plasma concentration; MRT, mean residence time; PK, pharmacokinetic; Tlag, apparent lag time between PO administration and appearance of menthol in plasma; Tmax, time of Cmax.

![Mean (± 95% confidence interval) plasma concentration vs. time data for menthol in a cohort of six children with Irritable Bowel Syndrome given a single oral dose of peppermint oil containing approximately 83.0 mg of menthol \[top panel\] and individual plasma menthol concentration vs. time data \[bottom panel\].](bmjopen2015008375f01){#BMJOPEN2015008375F1}

A summary of the PK parameters (mean, SD and 95% CIs) is provided in [table 2](#BMJOPEN2015008375TB2){ref-type="table"}. As reflected by the values for the CV for each of the parameters, the least variability was observed for MRT (CV=15.4%) and AUCtot (14.4%).

###### 

Summary of menthol pharmacokinetic parameters

  Parameter                            mean±SD        95% CI               CV%
  ------------------------------------ -------------- -------------------- ------
  Cmax (ng/mL)                         698.2±245.4    (501.8 to 894.6)     35.1
  Cmax (ng/mL per mg/kg)               361.8±80.8     (297.2 to 426.5)     22.3
  Tmax (h)                             5.3±2.4        (3.3 to 7.2)         45.3
  Tlag (h)                             2.0±1.0        (1.2 to 2.8)         50.0
  AUClast (ng/mL×h)                    3562.0±616.7   (3068.5 to 4055.4)   17.3
  AUC last (ng/mL×h per mg/kg dose)    1951.3±602.8   (1468.9 to 2433.7)   30.9
  AUCtot (ng/mL×h)                     4039.7±583.8   (3572.6 to 4506.9)   14.4
  AUC total (ng/mL×h per mg/kg dose)   2207.8±613.8   (1716.7 to 2698.9)   27.8
  %AUC extrapolated                    12.1±5.3       (7.8 to 16.3)        43.8
  MRT (h)                              7.8±1.2        (6.8 to 8.8)         15.4

AUC, area under the plasma concentration versus time curve; Cmax, apparent peak plasma concentration; CV, coefficient of variation MRT, mean residence time; Tlag, apparent lag time between PO administration and appearance of menthol in plasma; Tmax, time of Cmax.[Figure 1](#BMJOPEN2015008375F1){ref-type="fig"} Mean (±95% CI) plasma concentration versus time data for menthol in a cohort of six children with irritable bowel syndrome given a single oral dose of peppermint oil containing approximately 83.0 mg of menthol (top panel) and individual plasma menthol concentration versus time data (bottom panel).

Discussion {#s4}
==========

The putative active ingredient contained in PMO is menthol, a plant-derived, semivolatile monoterpene. The clinical pharmacology of menthol, with an emphasis on its interaction with sensory neurons (TRP channels), has been recently reviewed.[@R11] The disposition and PKs of menthol derived from the ingestion of PMO in adults also has been reported previously[@R10] [@R12] [@R13] as have the PKs of [l]{.smallcaps}[-]{.smallcaps}menthol administered directly to the upper gastrointestinal tract.[@R14] In a cohort of 12 adults administered an oral dose of [l]{.smallcaps}-menthol (10 and 100 mg), the drug was rapidly metabolised with conversion to a menthol glucuronide that could be measured in plasma and urine.[@R10] In a similar study of 16 adults reported by Mascher *et al*,[@R13] the apparent time of peak plasma concentration (Tmax) of menthol (measured by GC/MS) following oral administration of a 180 mg dose of enteric coated PMO occurred at approximately 3 h following drug administration. The decline of methanol levels in the plasma was rapid, with an average apparent elimination half-life of approximately 3.5 h.

Recent studies have shown that menthol clearance from plasma is associated with the activity of CYP2A6,[@R15] a polymorphically expressed cytochrome P450 isoform that is responsible for the biotransformation of other xenobiotics such as the primary nicotine metabolite, cotinine,[@R16] and the commonly used antimicrobial agent, metronidazole.[@R17] In the case of cotinine, Dempsey *et al*[@R16] demonstrated that *CYP2A6* genotype (a surrogate for CYP2A6 phenotype), as opposed to age, was the major determinant of cotinine plasma elimination half-life in infants and children. To date, the PK of menthol have not been evaluated or reported in a paediatric patient cohort. Thus, there are no data upon which to base the development of PMO dosing regimens for children or adolescents with IBS to produce desired levels of systemic menthol exposure.

Despite data from only a single available paediatric trial of PMO in children with IBS,[@R7] the substance is being increasingly used either as adjunctive or primary treatment of patients with this disorder based on anecdotal evidence of symptomatic improvement. It is not known whether the potential analgesic effects of menthol in patients with IBS have a central[@R18] and/or local basis. In contrast, the antispasmodic effects appear to be modulated locally as demonstrated by Hiki *et al*[@R14] in a study where *L*-menthol was directly sprayed onto gastric mucosa. It is for this reason that the Colpermin formulation of PO is in an enteric-coated solid oral dosage form and designed to release the active ingredients at a pH encountered in the small intestine (ie,\>6.5).[@R19]

As illustrated in the [figure 1](#BMJOPEN2015008375F1){ref-type="fig"}, the appearance of menthol in the plasma of all subjects in our cohort was delayed with an average lag time of 2 h, a finding consistent with aggregate data in adults summarised by the manufacturer of our test article.[@R19] This finding is supported to some extent by two earlier studies of the Colpermin product which examined the PKs of menthol in adults using urinary menthol excretion data[@R12] [@R20] and a more recent adult study which examined menthol concentrations in plasma following the administration of a different enteric-coated PMO product (Enteroplant, Spitzner Pharmaceuticals, Ettlingen, Germany).[@R13] Unlike the plasma concentration profile reported by Mascher *et al*,[@R13] the mean plasma-menthol concentration versus time data in our paediatric study cohort ([figure 1](#BMJOPEN2015008375F1){ref-type="fig"}; top panel) demonstrated an apparent prolonged absorption time with apparent peak plasma concentrations (Tmax) occurring between 2.5 and 8 h postdose ([table 1](#BMJOPEN2015008375TB1){ref-type="table"}). Reasons for the delayed Tmax likely reside with formulation-specific factors (ie, delayed release) and potentially, enterohepatic recirculation as menthol undergoes biotransformation by UDP-glucuronosyltransferase 2B7 (UGT2B7).[@R21] [@R22] The apparent post-Tmax increase in plasma-methanol concentrations in several of our study participants ([figure 1](#BMJOPEN2015008375F1){ref-type="fig"}, bottom panel) suggests the presence of enterohepatic recirculation.

In contrast to the adult data reported by Mascher *et al*,[@R13] we were not able to reliably estimate the apparent terminal elimination rate constant (λz) for menthol in our entire patient cohort; namely, patients 2, 4 and 6 where ≤2 post-Cmax plasma concentrations were available for estimation of the parameter. It was for this reason that we chose to use a non-compartmental approach to describe menthol PKs and to examine MRT as a parameter reflecting drug elimination. As noted above, our inability to produce a reliable estimate of λz precluded our reporting reliable estimates for the apparent plasma clearance and/or volume of distribution for menthol. Also, given the prolonged absorption of menthol in our cohort ([figure 1](#BMJOPEN2015008375F1){ref-type="fig"}), estimation of λz may have produced an errant result consequent to the phenomenon of the 'flip-flop model' which occurs when the rate of absorption and/or distribution is slower than the rate of true drug elimination.[@R23] Nonetheless, based on known patterns of ontogeny with regard to the activity of UGT isoforms,[@R8] we would not expect that the apparent elimination half-life of menthol in our study participants (ie, range from 1.6 to 3.0 h in three patients with reliable λz estimates) would be similar to values for this parameter (3.5 to 4.4 h) previously reported from adults.[@R13] A more accurate estimate of λz would have been available in our cohort had we previously had knowledge of the prolonged menthol absorption profile. This would have enabled us revise our blood sampling paradigm to cluster observations between 6 and 18 h postdose and to extend the sampling interval to 24 h.

Despite considerable variability in the plasma-menthol concentration versus time data in our patients ([figure 1](#BMJOPEN2015008375F1){ref-type="fig"}), the values for the AUCtot and MRT had the smallest coefficients of variation associated with them ([table 2](#BMJOPEN2015008375TB2){ref-type="table"}). This relatively close agreement in the PK parameters suggested by the coefficients of variation would seemingly support that despite the presence of allelic variants for *CYP2A6*[@R16] and *UGT2B7*[@R22] in the general population, the concentration versus time data for menthol in our cohort did not appear to contain an 'outlier' which could have been attributable to one or more of the participants having inherited an allelic variant for either of these genes.

Admittedly, the results from our exploratory study are descriptive and given the small size of the study cohort, may not be generalisable to a larger population of paediatric patients with IBS. The potential value of our findings resides with the provision of preliminary PK data for menthol in paediatric patients that could be used to inform and enrich the design of future trials to explore the link between menthol PK and PDs in patients with IBS or other disorders such as functional dyspepsia. For example, it is widely known that gastroparesis and delayed emptying can be seen in patients with IBS, with gastrointestinal symptoms having an association with the degree of gastroparesis.[@R24] Use of a non-invasive technique, such as ingestion of a small magnetic pill which is capable of providing objective information regarding motility of the entire gastrointestinal tract,[@R25] could enable one to easily explore PK--PD relationships for menthol in patients with IBS. Such information will be critical in objectively determining the effect and efficacy of menthol in the treatment of this disorder in children and adolescents.

Recently, the European Medicines Agency has issued a public statement on the use of herbal medicinal products containing pulegone and menthofuran, two minor constituents (0.5--4.6% and 1--9%, respectively) of *M. piperita* oils.[@R26] Concerns regarding the potential associations of these compounds and hepatotoxicity in persons with a high daily intake of PMO will likely spawn a renewed interest in this natural product, especially when it is used in a therapeutic context. While the quantitation of pulegone or menthofuran from the plasma samples of our study participants or the test article was beyond the scope of our study, the human health consequences of their presence as 'contaminants' of commercially available PMO formulations are not yet known. Nonetheless, the data from our exploratory study of PMO may have utility in future studies designed to evaluate the dose--concentration--effect relationship for PMO and any compounds contained therein.

Conclusions {#s5}
===========

Our pilot study demonstrates that the PK of menthol, the active ingredient in PMO, can be adequately characterised in paediatric patients with IBS. It is important to recognise that formulation-specific differences between PMO-containing products can markedly influence the plasma--menthol concentration versus time curve. Such differences must be considered in the design of PK-PD studies of menthol in this disorder so as to enable an accurate characterisation of the concentration--effect relationship.
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